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determine adherence to treatment guidelines. METHODS: In a
retrospective database study, continuously enrolled patients aged
18 years and older with COPD (COPD only or COPD+asthma),
who initiated therapy during year 2002 with either an inhaled
corticosteroid or an anticholinergic (ﬁrst ﬁll date identiﬁed as
index date) were included in the analyses. The severity of iden-
tiﬁed subjects was determined using two METHODS: respira-
tory disease-related health care utilization; and charlson
comorbid score during the one-year baseline period. Presence of
comorbid conditions was also determined. RESULTS: Of the
8392 patients identiﬁed as having COPD, 467 (5.56%) initiated
an inhaled corticosteroid and 495 (5.90%) initiated an anti-
cholinergic. Using respiratory related healthcare utilization in the
baseline period as a proxy for disease severity, 82% of inhaled
corticosteroid users were low utilizers, 14% were moderate uti-
lizers and 4% were high utilizers whereas 53% of anticholiner-
gic users were low utilizers, 31% were moderate utilizers and
16% were high utilizers. At baseline, mean Charlson comorbid-
ity score was signiﬁcantly lower among inhaled corticosteroid
users (0.88) as compared to anticholinergic users (1.32). Also, at
baseline anticholinergic users had a signiﬁcantly higher percent-
age of patients with comorbid diagnosis of congestive heart
failure, atherosclerosis, coronary heart disease, hypertension,
mental illness and other lung disease. Results were also consis-
tent in the COPD only group. All differences were signiﬁcant at
p < 0.05. CONCLUSIONS: Patients initiating an inhaled cor-
ticosteroid appeared to be less severe as indicated by lower 
health care utilization, lower Charlson comorbid score and 
fewer comorbid conditions than those patients initiated on 
anticholinergics.
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OBJECTIVE: Neurogenic bladder is a condition that involves
bladder dysfunction caused due to damage to any part of the
nervous system. Patients with neurogenic bladder encounter dif-
ﬁculties such as bladder overactivity, urinary incontinence, and
urge incontinence. The objective of this study was to assess the
prevalence of neurogenic bladder in patients with different neu-
rological conditions. METHODS: A thorough literature search
was performed using MEDLINE and other databases such as
HAPI, OVID, and ScienceDirect. Information related to neuro-
genic bladder, speciﬁcally estimates of proportion of patients suf-
fering from neurogenic bladder was obtained from this search.
Articles that were published between the years 1995–2004 were
included. Percentages obtained from the literature were com-
bined with prevalence data of various neurologic disorders avail-
able on National Center for Health Statistics website to obtain
estimated number of patients with different neurologic condi-
tions suffering from neurogenic bladder. RESULTS: Neurogenic
bladder is found to be most prevalent in patients with Stroke,
Parkinson’s disease, Traumatic Brain injury, Dementia, Spinal
Cord injury, Multiple Sclerosis, Spina Biﬁda and paralysis. It is
found to be prevalent in more than half of patients suffering from
Stroke which is estimated to be more than two million. Its preva-
lence in Parkinson’s patients varies widely between 0.2–0.7
million (27–70%). Occurrence of urinary incontinence due to
neurogenic bladder in patients with Dementia was 11–90%, an
estimate of approximately 0.2–1.5 million, depending on the
setting in which the patients are treated. Bladder overactivity has
been detected in 50–90% of patients with Multiple Sclerosis and
in 95% of patients with Spina Biﬁda, together accounting for an
estimated half million patients. CONCLUSIONS: There is a high
prevalence of bladder dysfunction in patients suffering with
nervous system disorder in the US. Further research should focus
on obtaining more precise estimates using a national level data
to determine trends of neurogenic bladder.
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OBJECTIVES: To evaluate the association between comorbidi-
ties and drug use with the risk of in-hospital fall in adult Chronic
Kidney Disease (CKD) patients. METHODS: A retrospective
case-control study was conducted at a University medical center
between January 1, 1998 and June 30, 2003. To be included as
a case, patients had to experience an in-hospital fall, ≥18 years
of age and, hospitalized for >24 hours. All patients had CKD
deﬁned as a glomerular ﬁltration rate less than 60ml/min on
admission. For every case, a matched control was identiﬁed in a
1 :2 ratio. Cases and controls were matched on CKD, age and
gender. Comorbidities were identiﬁed using ICD-9 CM diagno-
sis codes. Drug utilization was identiﬁed two days before the fall
date for cases and the reference fall date for controls. Statistics
performed were T-tests, chi-square, and conditional logistic
regression using “fall” as the dependent variable and race,
comorbidities and drug groups as covariates. RESULTS: There
were 635 fall cases that met study criteria. The mean age was 68
± 15 years, 54% were female, and 82% were Caucasian. Cases
were more likely to have congestive heart failure (33% vs. 27%),
diabetes (39% vs. 32%), dementia (6% vs. 2%) and pneumonia
(14% vs. 8%) and be receiving antidepressants (29% vs 19%),
antipsychotics (16% vs 13%) and anticonvulsants (15% vs
10%). Compared to controls, cases have multiple comorbidities
(54% vs 43%, p < 0.001) and received multiple drug 
groups (48% vs. 40%, p < 0.002) prior to the fall. Regression
analysis showed that CKD patients with dementia (OR 2.4, p =
0.001) and those receiving antidepressants (OR 1.5, p = 0.001)
and anticonvulsants (OR 1.5, p = 0.008) were more likely to
experience an in-hospital fall. CONCLUSION: The largest
health status risk factor for falling in CKD patients was 
dementia. Drugs associated with falling were antidepressants and
anticonvulsants.
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OBJECTIVE: To examine the economic impact of pharma-
cotherapy (PT) versus non-pharmacologic management (NPM)
among elderly patients with overactive bladder (OAB).
METHODS: Data were obtained from the PharMetrics Patient-
Centric Database on continuously beneﬁt-eligible patients ≥65
years of age diagnosed with OAB between January 2002 and
